The AMGEN Inc. International
Prize for
Therapeutic Advancement in Nephrology
The International Society
of Nephrology (ISN) is delighted to announce the first winner of the AMGEN
Inc. International Prize for Therapeutic Advancement in Nephrology.
The ISN AMGEN Inc. International
Prize was established earlier this year with the generous support of AMGEN Inc.
to recognize those who have increased our understanding and treatment of kidney
disease, through basic or clinical scientific research leading to therapeutic
advances.
During the World Congress
of Nephrology 2003 in Berlin Barry M. Brenner, M.D., of the
Harvard Medical School and Director Emeritus of the Renal Division, Brigham
and Women’s Hospital, Boston, MA (USA) will receive $50,000 for establishing
the foundations of our understanding of the progression of chronic kidney disease
and its retardation by blockade of the renin angiotensin system in experimental
and clinical studies leading to major benefit for millions of patients with
diabetes, hypertension and other kidney disease.
Dr. Brenner’s research was selected
from amongst seven entries generated from the USA, Europe, Middle East and the
Asian Pacific region. The Advisory Committee responsible for identifying the
winner included Steve Hebert of Yale University School of Medicine, New Haven,
CT (USA); Kiyoshi Kurokawa of Tokai University, Isehara (Japan); Andrew J. Rees
of University of Aberdeen, Department of Medicine & Therapeutics, Aberdeen
(UK) and was chaired by John H. Dirks of The University of Toronto.
Dr. Brenner will be honored
and awarded his prize check during the official ISN Prize Ceremony &
Presentations to be held during the World Congress of Nephrology at
16.30 on Monday, June 9 in Berlin.
At this time he will share
his key findings in a presentation entitled: RAS Blockade Opens the
Road to Remission of Renal Disease.
13 May 2003